UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 15

of '转移性黑素瘤的分子靶向治疗'

15
TI
Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma
AU
Chapman PB, Hauschild A, Robert C, et AL
SO
J Clin Oncol. 2012;30(15_suppl):8502.
 
AD